Assessment of visual function in patients with gyrate atrophy who are considered candidates for gene replacement

Rafael C. Caruso, Robert B. Nussenblatt, Karl G. Csaky, David Valle, Muriel I. Kaiser-Kupfer

Research output: Contribution to journalArticle

Abstract

Objective: To assess the course of change of visual function outcome variables in 5 patients with gyrate atrophy before a gene replacement therapy clinical trial. Methods: The outcome variables selected were visual field sensitivity and electroretinogram amplitude. The course of change of these outcome variables was determined by calculation of their half-lives. Results: In the 4 to 6 years during which each patient was followed up for this study, median visual field half-lives were 17.0 years (static perimetry) and 11.4 years (kinetic perimetry). Median electroretinogram half-lives were 16.0 years (maximal response) and 10.7 years (flicker response). Conclusions: The course of the decline of visual function outcome variables is frequently slow. Thus, a long-term clinical trial would be required to assess the efficacy of the intervention in the preservation of visual function.

Original languageEnglish (US)
Pages (from-to)667-669
Number of pages3
JournalArchives of Ophthalmology
Volume119
Issue number5
StatePublished - 2001

Fingerprint

Gyrate Atrophy
Visual Field Tests
Visual Fields
Clinical Trials
Genetic Therapy
Genes

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Caruso, R. C., Nussenblatt, R. B., Csaky, K. G., Valle, D., & Kaiser-Kupfer, M. I. (2001). Assessment of visual function in patients with gyrate atrophy who are considered candidates for gene replacement. Archives of Ophthalmology, 119(5), 667-669.

Assessment of visual function in patients with gyrate atrophy who are considered candidates for gene replacement. / Caruso, Rafael C.; Nussenblatt, Robert B.; Csaky, Karl G.; Valle, David; Kaiser-Kupfer, Muriel I.

In: Archives of Ophthalmology, Vol. 119, No. 5, 2001, p. 667-669.

Research output: Contribution to journalArticle

Caruso, RC, Nussenblatt, RB, Csaky, KG, Valle, D & Kaiser-Kupfer, MI 2001, 'Assessment of visual function in patients with gyrate atrophy who are considered candidates for gene replacement', Archives of Ophthalmology, vol. 119, no. 5, pp. 667-669.
Caruso, Rafael C. ; Nussenblatt, Robert B. ; Csaky, Karl G. ; Valle, David ; Kaiser-Kupfer, Muriel I. / Assessment of visual function in patients with gyrate atrophy who are considered candidates for gene replacement. In: Archives of Ophthalmology. 2001 ; Vol. 119, No. 5. pp. 667-669.
@article{769b785e89454e229f01a8fc5d05f38e,
title = "Assessment of visual function in patients with gyrate atrophy who are considered candidates for gene replacement",
abstract = "Objective: To assess the course of change of visual function outcome variables in 5 patients with gyrate atrophy before a gene replacement therapy clinical trial. Methods: The outcome variables selected were visual field sensitivity and electroretinogram amplitude. The course of change of these outcome variables was determined by calculation of their half-lives. Results: In the 4 to 6 years during which each patient was followed up for this study, median visual field half-lives were 17.0 years (static perimetry) and 11.4 years (kinetic perimetry). Median electroretinogram half-lives were 16.0 years (maximal response) and 10.7 years (flicker response). Conclusions: The course of the decline of visual function outcome variables is frequently slow. Thus, a long-term clinical trial would be required to assess the efficacy of the intervention in the preservation of visual function.",
author = "Caruso, {Rafael C.} and Nussenblatt, {Robert B.} and Csaky, {Karl G.} and David Valle and Kaiser-Kupfer, {Muriel I.}",
year = "2001",
language = "English (US)",
volume = "119",
pages = "667--669",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Assessment of visual function in patients with gyrate atrophy who are considered candidates for gene replacement

AU - Caruso, Rafael C.

AU - Nussenblatt, Robert B.

AU - Csaky, Karl G.

AU - Valle, David

AU - Kaiser-Kupfer, Muriel I.

PY - 2001

Y1 - 2001

N2 - Objective: To assess the course of change of visual function outcome variables in 5 patients with gyrate atrophy before a gene replacement therapy clinical trial. Methods: The outcome variables selected were visual field sensitivity and electroretinogram amplitude. The course of change of these outcome variables was determined by calculation of their half-lives. Results: In the 4 to 6 years during which each patient was followed up for this study, median visual field half-lives were 17.0 years (static perimetry) and 11.4 years (kinetic perimetry). Median electroretinogram half-lives were 16.0 years (maximal response) and 10.7 years (flicker response). Conclusions: The course of the decline of visual function outcome variables is frequently slow. Thus, a long-term clinical trial would be required to assess the efficacy of the intervention in the preservation of visual function.

AB - Objective: To assess the course of change of visual function outcome variables in 5 patients with gyrate atrophy before a gene replacement therapy clinical trial. Methods: The outcome variables selected were visual field sensitivity and electroretinogram amplitude. The course of change of these outcome variables was determined by calculation of their half-lives. Results: In the 4 to 6 years during which each patient was followed up for this study, median visual field half-lives were 17.0 years (static perimetry) and 11.4 years (kinetic perimetry). Median electroretinogram half-lives were 16.0 years (maximal response) and 10.7 years (flicker response). Conclusions: The course of the decline of visual function outcome variables is frequently slow. Thus, a long-term clinical trial would be required to assess the efficacy of the intervention in the preservation of visual function.

UR - http://www.scopus.com/inward/record.url?scp=0035016875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035016875&partnerID=8YFLogxK

M3 - Article

C2 - 11346393

AN - SCOPUS:0035016875

VL - 119

SP - 667

EP - 669

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 5

ER -